Routine foreskin pathology in adults: Low yield, high cost-Time to change practice?
4 affiliations
- 1Department of Urology University of Edinburgh, Western General Hospital Edinburgh UK.
- 2Centre for Medical Informatics, Usher Institute University of Edinburgh Edinburgh UK.
- 3Department of Pathology Western General Hospital Edinburgh UK.
- 4Institute of Genetics and Cancer University of Edinburgh Edinburgh UK.
Abstract
This study aimed to determine the diagnostic yield for malignant lesions and cost-effectiveness of routine foreskin pathology in adults. A retrospective audit was conducted of all adult circumcisions (age ≥16) performed between January 2015 and February 2025 at a UK tertiary centre. Clinical and pathology records were reviewed to identify unexpected cancer diagnoses-defined as cases with no prior biopsy evidence or clinical suspicion. The number needed to screen (NNS) to detect one cancer was calculated, and pathology costs were estimated based on local processing costs and the pathologist workload score for each sample. There were 2503 adult circumcisions performed between 2015 and 2025, with 2.6% (n = 66/2503) cancers detected on pathological assessment. Of these, 78.8% (n = 52/66) patients with confirmed penile cancer had clinically suspicious findings pre-operatively. Therefore, the NNS on routine pathology for unexpected cancers was 109.4 (95% CI = 65.4-183.4), and only one clinically significant cancer (7.1%, n = 1/14 [0.04% overall cohort]) required further treatment (topical ablation). The diagnostic yield was also age-dependent, with low diagnostic yields in patients below age 40 with potentially suspicious pathology (NNS = 178.5, 95% CI: 49.5-650.3). Pathology-associated costs were estimated at £65 584 over the study period (£994 per cancer identified). Targeting pathology to men aged ≥40 with clinical suspicion of cancer would reduce costs by 73.3% (£48 074), while reducing the cost per cancer detected to £350. Routine foreskin pathology after adult circumcision has a low diagnostic yield for unexpected malignancy and rarely alters management. Targeting pathology to higher yield patient groups may optimise resource use, aligning with national guidelines and delivering substantial cost savings.
Related
- Oral Semaglutide in Routine Clinical Practice: 24‐Month Real‐World Effectiveness, Persistence and Safety in Adults With Type 2 Diabetes
- AGE-related efficacy and safety of darolutamide triplet therapy in metastatic hormone-sensitive prostate cancer: are we ready for routine clinical practice?
- Routine Vitamin and Iron Biomarkers Do Not Explain Variation in Anti-Müllerian Hormone: Implications for Ovarian Reserve Testing in Clinical Practice
- Exploratory Comparison of Routine Inflammatory Biomarkers in Nasopharyngeal Carcinoma and Benign Adenoid-Associated Pathology.
- Ten simple rules to build genomics capacity for routine laboratory practice in the Global South
BibTeX
@article{mclean2026routine,
title = {{Routine foreskin pathology in adults: Low yield, high cost-Time to change practice?}},
author = {Kenneth A McLean and Ellen Gardner and Kathryn Kirkwood and C J Shukla and Alexander Laird and James P Blackmur},
journal = {BJUI compass},
year = {2026},
month = nov,
doi = {10.1002/bco2.70299},
url = {https://europepmc.org/article/MED/42999787},
note = {CC BY},
}
RIS
TY - JOUR
TI - Routine foreskin pathology in adults: Low yield, high cost-Time to change practice?
AU - Kenneth A McLean
AU - Ellen Gardner
AU - Kathryn Kirkwood
AU - C J Shukla
AU - Alexander Laird
AU - James P Blackmur
PY - 2026
DA - 2026/11/06
JO - BJUI compass
DO - 10.1002/bco2.70299
UR - https://europepmc.org/article/MED/42999787
AB - This study aimed to determine the diagnostic yield for malignant lesions and cost-effectiveness of routine foreskin pathology in adults. A retrospective audit was conducted of all adult circumcisions (age ≥16) performed between January 2015 and February 2025 at a UK tertiary centre. Clinical and pathology records were reviewed to identify unexpected cancer diagnoses-defined as cases with no prior biopsy evidence or clinical suspicion. The number needed to screen (NNS) to detect one cancer was calculated, and pathology costs were estimated based on local processing costs and the pathologist workload score for each sample. There were 2503 adult circumcisions performed between 2015 and 2025, with 2.6% (n = 66/2503) cancers detected on pathological assessment. Of these, 78.8% (n = 52/66) patients with confirmed penile cancer had clinically suspicious findings pre-operatively. Therefore, the NNS on routine pathology for unexpected cancers was 109.4 (95% CI = 65.4-183.4), and only one clinically significant cancer (7.1%, n = 1/14 [0.04% overall cohort]) required further treatment (topical ablation). The diagnostic yield was also age-dependent, with low diagnostic yields in patients below age 40 with potentially suspicious pathology (NNS = 178.5, 95% CI: 49.5-650.3). Pathology-associated costs were estimated at £65 584 over the study period (£994 per cancer identified). Targeting pathology to men aged ≥40 with clinical suspicion of cancer would reduce costs by 73.3% (£48 074), while reducing the cost per cancer detected to £350. Routine foreskin pathology after adult circumcision has a low diagnostic yield for unexpected malignancy and rarely alters management. Targeting pathology to higher yield patient groups may optimise resource use, aligning with national guidelines and delivering substantial cost savings.
SN - 2688-4526
ER -